Search

Search Results

• 

  Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment

  Marina Romozzi, Andrea Burgalassi, Catello Vollono, Maria Albanese, Giulia Vigani, Francesco De Cesaris, Alberto Chiarugi, Paolo Calabresi, Luigi Francesco Iannone

  07-05-2024

  https://doi.org/10.4081/cc.2024.15762

  3866

  PDF: 610
• 

  Intraparenchymal cerebral hemorrhage in a patient undergoing treatment with galcanezumab: the importance of adequate blood pressure control

  Yan Tereshko, Antonio Taglialatela, Iacopo Cancelli, Enrico Belgrado, Lorenzo Verriello, Giovanni Merlino, Mariarosaria Valente

  05-09-2025

  https://doi.org/10.4081/cc.2025.15786

  676

  PDF: 197
• 

  Exploring the cortical effect of monoclonal antibodies against CGRP ligand: a pilot study of the cortical silent period in migraine

  Gabriele Sebastianelli, Giulia Rosaria Melis, Chiara Abagnale, Francesco Casillo, Cherubino Di Lorenzo, Mariano Serrao, Gianluca Coppola

  09-05-2025

  https://doi.org/10.4081/cc.2025.15778

  1632

  PDF: 374

• PO-43 | Eptinezumab in migraine patients unresponsive to prior subcutaneous CGRP(-R) monoclonal antibody treatment: a retrospective case series Elena Cresta, Irene Mattioli, Michele Di Pasquale, Alice Lanfranchi, Renata Rao, Alessandro Padovani | Neurology Unit and Headache Centre, Dipartimento di continuità di cura e fragilità, ASST Spedali Civili e Università degli studi di Brescia, Brescia, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15865

  268

• PO-41 | Eptinezumab for difficult-to-treat migraine: who responds and who needs more Alessandro Visentini,^1,2,3 Roberta Messina,^1,2,3 Ilaria Cetta,^1,2,3 Edorardo Ratto,¹ Laura Zanandrea,^1,3 Federica Genovese,^1,2,3 Irene Chinali,¹ Bruno Colombo,¹ Massimo Filippi^1,2,3 | ¹Neurology Unit and ²Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; ³Vita-Salute San Raffaele University, Milan, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15863

  265

• PO-62 | Preventive migraine treatment in patients under 25: a 24-month observational study on adherence, therapeutic switching, and prescription determinant factors Marilena Marcosano,¹ Nicoletta Brunelli,¹ Luisa Fofi,¹ Laura Papetti,² Fabiana Ursitti,² Massimiliano Valeriani,² Fabrizio Vernieri,¹ Claudia Altamura¹ | ¹Headache and Neurosonology Unit, Fondazione Policlinico Campus Biomedico di Rome, Rome, Italy; ²Developmental Neurology, Bambino Gesù Children Hospital, IRCCS, Rome, Italy

  Società Italiana per lo studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15885

  140